Cargando…

The JAK1/2 Inhibitor Baricitinib Mitigates the Spike-Induced Inflammatory Response of Immune and Endothelial Cells In Vitro

The purpose of this study was to examine the effect of the JAK-STAT inhibitor baricitinib on the inflammatory response of human monocyte-derived macrophages (MDM) and endothelial cells upon exposure to the spike S1 protein from SARS-CoV-2. The effect of the drug has been evaluated on the release of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barilli, Amelia, Visigalli, Rossana, Ferrari, Francesca, Recchia Luciani, Giulia, Soli, Maurizio, Dall’Asta, Valeria, Rotoli, Bianca Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496399/ https://www.ncbi.nlm.nih.gov/pubmed/36140425 http://dx.doi.org/10.3390/biomedicines10092324

Ejemplares similares

Growth Arrest of Alveolar Cells in Response to Cytokines from Spike S1-Activated Macrophages: Role of IFN-γ
por: Barilli, Amelia, et al.
Publicado: (2022)

Cytokine-Induced iNOS in A549 Alveolar Epithelial Cells: A Potential Role in COVID-19 Lung Pathology
por: Barilli, Amelia, et al.
Publicado: (2023)

Endothelial Cell Activation by SARS-CoV-2 Spike S1 Protein: A Crosstalk between Endothelium and Innate Immune Cells
por: Rotoli, Bianca Maria, et al.
Publicado: (2021)

y+LAT1 and y+LAT2 contribution to arginine uptake in different human cell models: Implications in the pathophysiology of Lysinuric Protein Intolerance
por: Rotoli, Bianca Maria, et al.
Publicado: (2019)

Flagellin From Pseudomonas Aeruginosa Stimulates ATB(0,+) Transporter for Arginine and Neutral Amino Acids in Human Airway Epithelial Cells
por: Barilli, Amelia, et al.
Publicado: (2021)

Desmopressin Stimulates Nitric Oxide Production in Human Lung Microvascular Endothelial Cells
por: Rotoli, Bianca Maria, et al.
Publicado: (2022)

Immune-Mediated Inflammatory Responses of Alveolar Epithelial Cells: Implications for COVID-19 Lung Pathology
por: Barilli, Amelia, et al.
Publicado: (2022)

Organic Cation Transporters (OCTs) in EpiAirway™, a Cellular Model of Normal Human Bronchial Epithelium
por: Barilli, Amelia, et al.
Publicado: (2020)

Expression and Function of ABC Transporters in Human Alveolar Epithelial Cells
por: Visigalli, Rossana, et al.
Publicado: (2022)

Analysis of LPI-causing mutations on y+LAT1 function and localization
por: Rotoli, Bianca Maria, et al.
Publicado: (2019)

Functional analysis of OCTN2 and ATB(0,+) in normal human airway epithelial cells
por: Rotoli, Bianca Maria, et al.
Publicado: (2020)

Correction: Functional analysis of OCTN2 and ATB(0,+) in normal human airway epithelial cells
por: Rotoli, Bianca Maria, et al.
Publicado: (2020)

Downregulation of SLC7A7 Triggers an Inflammatory Phenotype in Human Macrophages and Airway Epithelial Cells
por: Rotoli, Bianca Maria, et al.
Publicado: (2018)

Monocytes from infliximab-resistant patients with Crohn’s disease exhibit a disordered cytokine profile
por: Gaiani, Federica, et al.
Publicado: (2020)

Characterization of ABC Transporters in EpiAirway™, a Cellular Model of Normal Human Bronchial Epithelium
por: Rotoli, Bianca Maria, et al.
Publicado: (2020)

In Lysinuric Protein Intolerance system y(+)L activity is defective in monocytes and in GM-CSF-differentiated macrophages
por: Barilli, Amelia, et al.
Publicado: (2010)

Acrylamide Reduction Strategy in Combination with Deoxynivalenol Mitigation in Industrial Biscuits Production
por: Suman, Michele, et al.
Publicado: (2019)

JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
por: Sanchez, Gina A. Montealegre, et al.
Publicado: (2018)

A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
por: Taylor, Peter C., et al.
Publicado: (2023)

Efficacy of Combination Therapy With The JAK Inhibitor Baricitinib In The Treatment of COVID-19
por: Thoms, Brendan Lawless, et al.
Publicado: (2021)

Efficacy of Combination Therapy with the JAK Inhibitor Baricitinib in the Treatment of COVID-19
por: Thoms, Brendan L., et al.
Publicado: (2022)

Which is the Ideal JAK Inhibitor for Alopecia Areata – Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway
por: Sardana, Kabir, et al.
Publicado: (2023)

Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients
por: Radi, Giulia, et al.
Publicado: (2021)

Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
por: Jabbari, Ali, et al.
Publicado: (2015)

Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor
por: Scheinberg, Morton, et al.
Publicado: (2021)

Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib
por: Kay, Jonathan, et al.
Publicado: (2020)

Control of Multilayer Networks
por: Menichetti, Giulia, et al.
Publicado: (2016)

Inhibition of JAK-STAT Signaling with Baricitinib Reduces Inflammation and Improves Cellular Homeostasis in Progeria Cells
por: Liu, Chang, et al.
Publicado: (2019)

Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib
por: Nezamololama, Novin, et al.
Publicado: (2020)

JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib
por: Traves, Paqui G, et al.
Publicado: (2021)

JAK1/2 Inhibitor Baricitinib Improves Skin Fibrosis and Digital Ulcers in Systemic Sclerosis
por: Hou, Zhanying, et al.
Publicado: (2022)

Deoxynivalenol & Deoxynivalenol-3-Glucoside Mitigation through Bakery Production Strategies: Effective Experimental Design within Industrial Rusk-Making Technology
por: Generotti, Silvia, et al.
Publicado: (2015)

JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial
por: Tuttle, Katherine R, et al.
Publicado: (2018)

A Jak1/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro
por: Murakami, Kohei, et al.
Publicado: (2017)

Baricitinib, a JAK-STAT Inhibitor, Reduces the Cellular Toxicity of the Farnesyltransferase Inhibitor Lonafarnib in Progeria Cells
por: Arnold, Rouven, et al.
Publicado: (2021)

Corrigendum: JAK1/2 inhibitor baricitinib improves skin fibrosis and digital ulcers in systemic sclerosis
por: Hou, Zhanying, et al.
Publicado: (2023)

Inhibition of the JAK/STAT Pathway With Baricitinib Reduces the Multiple Organ Dysfunction Caused by Hemorrhagic Shock in Rats
por: Patel, Nikita M., et al.
Publicado: (2023)

Case report: JAK1/2 inhibition with baricitinib in the treatment of STING-associated vasculopathy with onset in infancy
por: Wu, Jianqiang, et al.
Publicado: (2023)

Forthcoming Challenges in Mycotoxins Toxicology Research for Safer Food—A Need for Multi-Omics Approach
por: Dellafiora, Luca, et al.
Publicado: (2017)

Application of Baricitinib in Dermatology
por: Zhang, Jingya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uoi72eo77gj309dmcucjfitnem